A. Kashiwagi, M. Shestakova, Yuichiro Ito, Masahiro Noguchi, W. Wilpshaar, S. Yoshida, John P H Wilding
{"title":"Ipragliflozin在2型糖尿病患者中的安全性:II/III/IV期临床试验的汇总分析","authors":"A. Kashiwagi, M. Shestakova, Yuichiro Ito, Masahiro Noguchi, W. Wilpshaar, S. Yoshida, John P H Wilding","doi":"10.1007/s13300-019-00699-8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"10 1","pages":"2201 - 2217"},"PeriodicalIF":2.8000,"publicationDate":"2019-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13300-019-00699-8","citationCount":"13","resultStr":"{\"title\":\"Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials\",\"authors\":\"A. Kashiwagi, M. Shestakova, Yuichiro Ito, Masahiro Noguchi, W. Wilpshaar, S. Yoshida, John P H Wilding\",\"doi\":\"10.1007/s13300-019-00699-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":48675,\"journal\":{\"name\":\"Diabetes Therapy\",\"volume\":\"10 1\",\"pages\":\"2201 - 2217\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2019-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s13300-019-00699-8\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13300-019-00699-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-019-00699-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
期刊介绍：
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
